Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    A Prospective, Open-label, Long-term Safety and Efficacy Study of Teduglutide in Japanese Pediatric Subjects with Short Bowel Syndrome Who Completed SHP633-302

    Summary
    EudraCT number
    2021-005404-36
    Trial protocol
    Outside EU/EEA  
    Global end of trial date
    02 Nov 2021

    Results information
    Results version number
    v1(current)
    This version publication date
    12 May 2022
    First version publication date
    12 May 2022
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    SHP633-305
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    NCT03268811
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    Shire
    Sponsor organisation address
    300 Shire Way, Lexington, United States, MA 02421
    Public contact
    Study Director, Shire, +1 866 842 5335, ClinicalTransparency@shire.com
    Scientific contact
    Study Director, Shire, +1 866 842 5335, ClinicalTransparency@shire.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    02 Nov 2021
    Is this the analysis of the primary completion data?
    No
    Global end of trial reached?
    Yes
    Global end of trial date
    02 Nov 2021
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    The primary objective of the study was to evaluate the long-term safety and tolerability of teduglutide treatment in Japanese pediatric participants with short bowel syndrome (SBS) who completed Study SHP633-302 (2020-005791-35).
    Protection of trial subjects
    This clinical study was conducted in accordance with the study protocol and the ethical principles that have their origin in the World Medical Association Declaration of Helsinki. In addition, it was consistent with the standards stipulated in Article 14, Paragraph 3, and Article 80-2 of the Law on Securing Quality, Efficacy and Safety of Products including Pharmaceuticals and Medical Devices in Japan, the “Ministerial Ordinance on the Standards for the Implementation of Clinical Studies on Pharmaceutical Product” in Japan, and International Council For Harmonisation (ICH) Good Clinical Practices (GCP).
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    23 Aug 2017
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    Yes
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Japan: 9
    Worldwide total number of subjects
    9
    EEA total number of subjects
    0
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    2
    Children (2-11 years)
    6
    Adolescents (12-17 years)
    1
    Adults (18-64 years)
    0
    From 65 to 84 years
    0
    85 years and over
    0

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    The study was conducted at 6 centers in Japan from 23 August 2017 (first participant first visit) and 02 November 2021 (last participant last visit).

    Pre-assignment
    Screening details
    A total of 9 Japanese pediatric participants who completed Study SHP633-302 (2020-005791-35) were enrolled into the extension study based on age of participants i.e., 7 children (aged 1 through 15 years of age) and 2 infants (aged 4 months through < 12 months of corrected gestational age).

    Period 1
    Period 1 title
    Overall Study (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Not applicable
    Blinding used
    Not blinded

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    Total Children (Aged: 1 to 15 Years)
    Arm description
    Participants aged from 1 through 15 years who participated in the core study (SHP633-302 [2020-005791-35]) were enrolled into this extension study and received teduglutide 0.05 milligram per kilogram (mg/kg) subcutaneous (SC) injection once daily for 24 weeks in each treatment cycle (Cycles 1 to 9 [Each cycle=28 weeks]) depending on the disease course.
    Arm type
    Experimental

    Investigational medicinal product name
    Teduglutide
    Investigational medicinal product code
    SHP633
    Other name
    Pharmaceutical forms
    Injection
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    Participants received teduglutide 0.05 mg/kg SC injection once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm.

    Arm title
    Infants (Corrected Gestational Age: 4 to < 12 Months)
    Arm description
    Participants (Infants) from 4 through < 12 months of corrected gestational age who participated in the core study (SHP633-302 [2020-005791-35]) were enrolled into this extension study and received teduglutide 0.05 mg/kg SC injection once daily for 24 weeks in each treatment cycle (Cycles 1 to 9 [Each cycle=28 weeks]) depending on the disease course.
    Arm type
    Experimental

    Investigational medicinal product name
    Teduglutide
    Investigational medicinal product code
    SHP633
    Other name
    Pharmaceutical forms
    Injection
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    Participants received teduglutide 0.05 mg/kg SC injection once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm.

    Number of subjects in period 1
    Total Children (Aged: 1 to 15 Years) Infants (Corrected Gestational Age: 4 to < 12 Months)
    Started
    7
    2
    Completed
    7
    1
    Not completed
    0
    1
         Adverse event, non-fatal
    -
    1

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Total Children (Aged: 1 to 15 Years)
    Reporting group description
    Participants aged from 1 through 15 years who participated in the core study (SHP633-302 [2020-005791-35]) were enrolled into this extension study and received teduglutide 0.05 milligram per kilogram (mg/kg) subcutaneous (SC) injection once daily for 24 weeks in each treatment cycle (Cycles 1 to 9 [Each cycle=28 weeks]) depending on the disease course.

    Reporting group title
    Infants (Corrected Gestational Age: 4 to < 12 Months)
    Reporting group description
    Participants (Infants) from 4 through < 12 months of corrected gestational age who participated in the core study (SHP633-302 [2020-005791-35]) were enrolled into this extension study and received teduglutide 0.05 mg/kg SC injection once daily for 24 weeks in each treatment cycle (Cycles 1 to 9 [Each cycle=28 weeks]) depending on the disease course.

    Reporting group values
    Total Children (Aged: 1 to 15 Years) Infants (Corrected Gestational Age: 4 to < 12 Months) Total
    Number of subjects
    7 2 9
    Age categorical
    Units: Subjects
        Aged: 1 to 15 Years
    7 0 7
        Corrected Gestation Age: 4 to < 12 months
    0 2 2
    Gender categorical
    Units: Subjects
        Male
    6 1 7
        Female
    1 1 2
    Race
    Units: Subjects
        American Indian or Alaska Native
    0 0 0
        Asian
    7 2 9
        Native Hawaiian or Other Pacific Islander
    0 0 0
        Black or African American
    0 0 0
        White
    0 0 0
        More than one race
    0 0 0
        Unknown or Not Reported
    0 0 0
    Ethnicity
    Units: Subjects
        Hispanic or Latino
    0 0 0
        Not Hispanic or Latino
    7 2 9
        Unknown or Not Reported
    0 0 0

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    Total Children (Aged: 1 to 15 Years)
    Reporting group description
    Participants aged from 1 through 15 years who participated in the core study (SHP633-302 [2020-005791-35]) were enrolled into this extension study and received teduglutide 0.05 milligram per kilogram (mg/kg) subcutaneous (SC) injection once daily for 24 weeks in each treatment cycle (Cycles 1 to 9 [Each cycle=28 weeks]) depending on the disease course.

    Reporting group title
    Infants (Corrected Gestational Age: 4 to < 12 Months)
    Reporting group description
    Participants (Infants) from 4 through < 12 months of corrected gestational age who participated in the core study (SHP633-302 [2020-005791-35]) were enrolled into this extension study and received teduglutide 0.05 mg/kg SC injection once daily for 24 weeks in each treatment cycle (Cycles 1 to 9 [Each cycle=28 weeks]) depending on the disease course.

    Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    Close Top of page
    End point title
    Number of Participants With Treatment-emergent Adverse Events (TEAEs) [1]
    End point description
    An Adverse Event (AE) was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. TEAEs were defined as any AEs whose onset occurred, severity worsened or intensity increased after receiving the investigational product (IP) in the core study (SHP633-302 [2020-005791-35]) or this extension study. The safety population included all enrolled participants in the study and who received at least one dose of teduglutide (in study SHP633-302 [2020-005791-35] or SHP633-305 [2021-005404-36]). Number of participants with TEAEs were reported. Baseline refers to the baseline value of the core study (SHP633-302 [2020-005791-35]).
    End point type
    Primary
    End point timeframe
    From Baseline up to follow-up (up to 50 months)
    Notes
    [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No statistical and comparison analyses were performed for this endpoint.
    End point values
    Total Children (Aged: 1 to 15 Years) Infants (Corrected Gestational Age: 4 to < 12 Months)
    Number of subjects analysed
    7
    2
    Units: Participants
    7
    2
    No statistical analyses for this end point

    Primary: Number of Participants With Clinically Significant Abnormalities in Vital Signs

    Close Top of page
    End point title
    Number of Participants With Clinically Significant Abnormalities in Vital Signs [2]
    End point description
    Vital sign assessments included pulse rate, blood pressure (systolic and diastolic blood pressure) and body temperature. Number of participants with clinically significant abnormalities in vital signs which were deemed clinically significant by the investigator were reported. The safety population included all enrolled participants in the study and who received at least one dose of teduglutide (in study SHP633-302 [2020-005791-35] or SHP633-305 [2021-005404-36]). Baseline refers to the baseline value of the core study (SHP633-302 [2020-005791-35]).
    End point type
    Primary
    End point timeframe
    From Baseline up to follow-up (up to 50 months)
    Notes
    [2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No statistical and comparison analyses were performed for this endpoint.
    End point values
    Total Children (Aged: 1 to 15 Years) Infants (Corrected Gestational Age: 4 to < 12 Months)
    Number of subjects analysed
    7
    2
    Units: Participants
    0
    0
    No statistical analyses for this end point

    Primary: Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters

    Close Top of page
    End point title
    Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters [3]
    End point description
    Clinical laboratory parameters included biochemistry, hematology and urinalysis. Number of participants with clinically significant abnormalities in laboratory parameters which were deemed clinically significant by the investigator were reported. The safety population included all enrolled participants in the study and who received at least one dose of teduglutide (in study SHP633-302 [2020-005791-35] or SHP633-305 [2021-005404-36]). Baseline refers to the baseline value of the core study (SHP633-302 [2020-005791-35]).
    End point type
    Primary
    End point timeframe
    From Baseline up to follow-up (up to 50 months)
    Notes
    [3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No statistical and comparison analyses were performed for this endpoint.
    End point values
    Total Children (Aged: 1 to 15 Years) Infants (Corrected Gestational Age: 4 to < 12 Months)
    Number of subjects analysed
    7
    2
    Units: Participants
        Biochemistry
    5
    1
        Hematology
    1
    0
        Urinalysis
    0
    0
    No statistical analyses for this end point

    Primary: Percent Change From Baseline in Average Total Urine Output at End of Treatment (EOT) of Last Cycle During Teduglutide Treatment

    Close Top of page
    End point title
    Percent Change From Baseline in Average Total Urine Output at End of Treatment (EOT) of Last Cycle During Teduglutide Treatment [4]
    End point description
    Average total urine output was recorded over a 48-hour period of parental support (PS) stability before every scheduled site visit and within 1 week of implementing any PS adjustment. The Average daily urine output milliliter per kilogram per day (mL/kg/day) was calculated as: (Total urine output over 48 hours / 2) / body weight (kilogram [kg]) where total urine output was calculated as the sum of the urine output in milliliter (mL) and the urine-only diaper weights in gram (g) (1g = 1mL) for the participant collected on the output diary form of electronic case report from (eCRF). Safety Population. Here, "number of participants analysed" refer to the participants evaluable for this endpoint. Baseline refers to the baseline value of the core study (SHP633-302 [2020-005791-35]).
    End point type
    Primary
    End point timeframe
    Baseline, EOT of last cycle (up to Month 45) (Each Cycle 1 to 8 = 24 weeks, and Cycle 9 = 4 weeks)
    Notes
    [4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No statistical and comparison analyses were performed for this endpoint.
    End point values
    Total Children (Aged: 1 to 15 Years) Infants (Corrected Gestational Age: 4 to < 12 Months)
    Number of subjects analysed
    6
    2
    Units: Percent Change
        arithmetic mean (standard deviation)
    -37.228 ( 42.9396 )
    146.881 ( 295.8061 )
    No statistical analyses for this end point

    Primary: Percent Change From Baseline in Average Number of Stools Per Day at EOT of Last Cycle During Teduglutide Treatment

    Close Top of page
    End point title
    Percent Change From Baseline in Average Number of Stools Per Day at EOT of Last Cycle During Teduglutide Treatment [5]
    End point description
    Fecal output was recorded over a 48-hour period of PS stability before every scheduled site visit and within 1 week of implementing any PS adjustment. The average daily fecal output was summarized by the average number of stools per day. The average number of stools per day was calculated as (sum of the daily data in a 48-hour period/2). The safety population included all enrolled participants in the study and who received at least one dose of teduglutide (in study SHP633-302 [2020-005791-35] or SHP633-305 [2021-005404-36]). Here, "number of participants analysed" refer to the participants evaluable for this endpoint. Percent change from baseline in average number of stools per day at EOT of last cycle during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 [2020-005791-35]).
    End point type
    Primary
    End point timeframe
    Baseline, EOT of last cycle (up to Month 45) (Each Cycle 1 to 8 = 24 weeks, and Cycle 9 = 4 weeks)
    Notes
    [5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No statistical and comparison analyses were performed for this endpoint.
    End point values
    Total Children (Aged: 1 to 15 Years) Infants (Corrected Gestational Age: 4 to < 12 Months)
    Number of subjects analysed
    6
    2
    Units: Percent Change
        arithmetic mean (standard deviation)
    24.37 ( 63.623 )
    50.00 ( 0.000 )
    No statistical analyses for this end point

    Primary: Percent Change From Baseline in Average Stool/Mixed Stool Diaper Weight at EOT of Last Cycle During Teduglutide Treatment

    Close Top of page
    End point title
    Percent Change From Baseline in Average Stool/Mixed Stool Diaper Weight at EOT of Last Cycle During Teduglutide Treatment [6]
    End point description
    Fecal output was recorded over a 48-hour period of PS stability before every scheduled site visit and within 1 week of implementing any PS adjustment. The average daily fecal output was summarized by the average stool/mixed stool diaper weight (gram per kilogram per day [g/kg/day]). The body weight was used to calculate the daily stool/mixed stool diaper weight (g/kg/day). Safety population. Here, "number of participants analysed" refer to the participants evaluable for this endpoint. Percent change from baseline in average stool/mixed stool diaper weight at EOT of last cycle during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 [2020-005791-35]). Here, '99999' indicates that standard deviation could not be estimated for single subject for the specified arm.
    End point type
    Primary
    End point timeframe
    Baseline, EOT of last cycle (up to Month 45) (Each Cycle 1 to 8 = 24 weeks, and Cycle 9 = 4 weeks)
    Notes
    [6] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No statistical and comparison analyses were performed for this endpoint.
    End point values
    Total Children (Aged: 1 to 15 Years) Infants (Corrected Gestational Age: 4 to < 12 Months)
    Number of subjects analysed
    1
    2
    Units: Percent Change
        arithmetic mean (standard deviation)
    -12.678 ( 99999 )
    206.017 ( 332.4580 )
    No statistical analyses for this end point

    Primary: Percent Change From Baseline in Average Total Ostomy Output at EOT of Last Cycle During Teduglutide Treatment

    Close Top of page
    End point title
    Percent Change From Baseline in Average Total Ostomy Output at EOT of Last Cycle During Teduglutide Treatment [7]
    End point description
    Fecal output was recorded over a 48-hour period of PS stability before every scheduled site visit and within 1 week of implementing any PS adjustment. The body weight was used to calculate the average total ostomy output per day (mL/kg/day) using a formula analogous to that used to calculate the average daily urine output. The safety population included all enrolled participants in the study and who received at least one dose of teduglutide (in study SHP633-302 [2020-005791-35] or SHP633-305 [2021-005404-36]). Here, "number of participants analysed" refer to the participants evaluable for this endpoint. Percent change from baseline in average total ostomy output at EOT of last cycle during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 [2020-005791-35]).
    End point type
    Primary
    End point timeframe
    Baseline, EOT of last cycle (up to Month 45) (Each Cycle 1 to 8 = 24 weeks, and Cycle 9 = 4 weeks)
    Notes
    [7] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No statistical and comparison analyses were performed for this endpoint.
    End point values
    Total Children (Aged: 1 to 15 Years) Infants (Corrected Gestational Age: 4 to < 12 Months)
    Number of subjects analysed
    0 [8]
    2
    Units: Percent Change
        arithmetic mean (standard deviation)
    ( )
    3.143 ( 145.8659 )
    Notes
    [8] - As no participant was analyzed for this arm, therefore data was not reported.
    No statistical analyses for this end point

    Primary: Percent Change From Baseline in Average Bristol Stool Form Score at EOT of Last Cycle During Teduglutide Treatment

    Close Top of page
    End point title
    Percent Change From Baseline in Average Bristol Stool Form Score at EOT of Last Cycle During Teduglutide Treatment [9]
    End point description
    Fecal output was recorded over a 48-hour period of PS stability before every scheduled site visit and within 1 week of implementing any PS adjustment. The average daily fecal output was summarized the average typical stool form score using Bristol Stool Form Scale. The average typical stool form score was calculated as (sum of the daily data in a 48-hour period / 2). Typical Stool Form based on Bristol Stool Form Scale: 1 - Separate hard lumps, hard to pass, 2 - Sausage-shaped, but lumpy, 3 - Like a sausage but with cracks on the surface, 4- Like a sausage or snake, smooth and soft, 5- Soft blobs with clear-cut edges, 6- Fluffy pieces with ragged edges, a mushy stool, 7- Watery, no solid pieces, Entirely liquid. Safety population. Here, "number of participants analysed" refer to the participants evaluable for this endpoint. Baseline refers to the baseline value of the core study (SHP633-302 [2020-005791-35]). A negative change from baseline indicates improvement.
    End point type
    Primary
    End point timeframe
    Baseline, EOT of last cycle (up to Month 45) (Each Cycle 1 to 8 = 24 weeks, and Cycle 9 = 4 weeks)
    Notes
    [9] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No statistical and comparison analyses were performed for this endpoint.
    End point values
    Total Children (Aged: 1 to 15 Years) Infants (Corrected Gestational Age: 4 to < 12 Months)
    Number of subjects analysed
    6
    2
    Units: Percent Change
        arithmetic mean (standard deviation)
    -7.51 ( 16.758 )
    0.00 ( 0.000 )
    No statistical analyses for this end point

    Primary: Number of Participants With Anti-drug antibodies (ADAs) (Including Neutralizing Antibodies) at EOT of Last Cycle During Teduglutide Treatment

    Close Top of page
    End point title
    Number of Participants With Anti-drug antibodies (ADAs) (Including Neutralizing Antibodies) at EOT of Last Cycle During Teduglutide Treatment [10]
    End point description
    Number of participants with ADAs (including NAbs) to teduglutide were used to summarize the presence of antibodies. The participants who tested positive for ADAs (including NAbs) were reported. The safety population included all enrolled participants in the study and who received at least one dose of teduglutide (in study SHP633-302 [2020-005791-35] or SHP633-305 [2021-005404-36]). Here, "number of participants analysed" signifies participants who were evaluable for this endpoint and "n" signifies to participants evaluable at given timepoints. Baseline refers to the baseline value of the core study (SHP633-302 [2020-005791-35]).
    End point type
    Primary
    End point timeframe
    Baseline, EOT of last cycle (up to Month 45) (Each Cycle 1 to 8 = 24 weeks, and Cycle 9 = 4 weeks)
    Notes
    [10] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No statistical and comparison analyses were performed for this endpoint.
    End point values
    Total Children (Aged: 1 to 15 Years) Infants (Corrected Gestational Age: 4 to < 12 Months)
    Number of subjects analysed
    6
    2
    Units: Participants
        Positive ADA: EOT of Last Cycle (n= 6, 2)
    5
    0
        Positive NAbs: EOT of Last Cycle (n= 5, 0)
    4
    0
    No statistical analyses for this end point

    Primary: Number of Participants With Clinically Significant Changes in Gastrointestinal (GI) Specific Testing

    Close Top of page
    End point title
    Number of Participants With Clinically Significant Changes in Gastrointestinal (GI) Specific Testing [11]
    End point description
    GI specific testing included colonoscopy or sigmoidoscopy, abdominal ultrasound, fecal occult blood testing, upper GI series with small bowel follow-through (UGI/SBFT). Number of participants with clinically significant changes findings in gastrointestinal specific testing were reported. The safety population included all enrolled participants in the study and who received at least one dose of teduglutide (in study SHP633-302 [2020-005791-35] or SHP633-305 [2021-005404-36]). Here, "number of participants analysed" refer to the participants evaluable for this endpoint. Baseline refers to the baseline value of the core study (SHP633-302 [2020-005791-35]).
    End point type
    Primary
    End point timeframe
    Baseline, EOT of last cycle (up to Month 45) (Each Cycle 1 to 8 = 24 weeks, and Cycle 9 = 4 weeks)
    Notes
    [11] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No statistical and comparison analyses were performed for this endpoint.
    End point values
    Total Children (Aged: 1 to 15 Years) Infants (Corrected Gestational Age: 4 to < 12 Months)
    Number of subjects analysed
    6
    2
    Units: Participants
    0
    0
    No statistical analyses for this end point

    Primary: Change From Baseline in Body Weight For Age Z-Score at EOT of Last Cycle During Teduglutide Treatment

    Close Top of page
    End point title
    Change From Baseline in Body Weight For Age Z-Score at EOT of Last Cycle During Teduglutide Treatment [12]
    End point description
    Body weight was measured using Age Z-score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age >= 2 years old) and World Health Organization (age < 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Safety population. Here, "number of participants analysed" refer to the participants evaluable for this endpoint. Change from baseline in body weight for age Z-Score at EOT of last cycle during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 [2020-005791-35]).
    End point type
    Primary
    End point timeframe
    Baseline, EOT of last cycle (up to Month 45) (Each Cycle 1 to 8 = 24 weeks, and Cycle 9 = 4 weeks)
    Notes
    [12] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No statistical and comparison analyses were performed for this endpoint.
    End point values
    Total Children (Aged: 1 to 15 Years) Infants (Corrected Gestational Age: 4 to < 12 Months)
    Number of subjects analysed
    6
    2
    Units: z-score
        arithmetic mean (standard deviation)
    0.229 ( 0.5636 )
    3.982 ( 3.6363 )
    No statistical analyses for this end point

    Primary: Change From Baseline in Height For Age Z-Score at EOT of Cycle 1 During Teduglutide Treatment

    Close Top of page
    End point title
    Change From Baseline in Height For Age Z-Score at EOT of Cycle 1 During Teduglutide Treatment [13]
    End point description
    Height was measured using Age Z-Score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age >= 2 years old) and World Health Organization (age < 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Safety population. Here, "number of participants analysed" refer to the participants evaluable for this endpoint. Change from baseline in height for age Z-Score at EOT of cycle 1 during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 [2020-005791-35]).
    End point type
    Primary
    End point timeframe
    Baseline, EOT of Cycle 1 (up to 24 Weeks)
    Notes
    [13] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No statistical and comparison analyses were performed for this endpoint.
    End point values
    Total Children (Aged: 1 to 15 Years) Infants (Corrected Gestational Age: 4 to < 12 Months)
    Number of subjects analysed
    6
    2
    Units: Z-score
        arithmetic mean (standard deviation)
    0.002 ( 0.6049 )
    1.376 ( 0.3363 )
    No statistical analyses for this end point

    Primary: Change From Baseline in Height For Age Z-Score at EOT of Cycle 2 During Teduglutide Treatment

    Close Top of page
    End point title
    Change From Baseline in Height For Age Z-Score at EOT of Cycle 2 During Teduglutide Treatment [14]
    End point description
    Height was measured using Age Z-Score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age >= 2 years old) and World Health Organization (age < 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Safety population. Here, "number of participants analysed" refer to the participants evaluable for this endpoint. Baseline refers to the baseline value of the core study (SHP633-302 [2020-005791-35]). Here, '99999' indicates that standard deviation could not be estimated for single subject for the specified arm.
    End point type
    Primary
    End point timeframe
    Baseline, EOT of Cycle 2 (up to 48 weeks)
    Notes
    [14] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No statistical and comparison analyses were performed for this endpoint.
    End point values
    Total Children (Aged: 1 to 15 Years) Infants (Corrected Gestational Age: 4 to < 12 Months)
    Number of subjects analysed
    6
    1
    Units: Z-score
        arithmetic mean (standard deviation)
    0.152 ( 0.5181 )
    3.114 ( 99999 )
    No statistical analyses for this end point

    Primary: Change From Baseline in Height For Age Z-Score at EOT of Cycle 3 During Teduglutide Treatment

    Close Top of page
    End point title
    Change From Baseline in Height For Age Z-Score at EOT of Cycle 3 During Teduglutide Treatment [15]
    End point description
    Height was measured using Age Z-Score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age >= 2 years old) and World Health Organization (age < 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Safety population. Here, "number of participants analysed" refer to the participants evaluable for this endpoint. Baseline refers to the baseline value of the core study (SHP633-302 [2020-005791-35]). Here, '99999' indicates that standard deviation could not be estimated for single subject for the specified arm.
    End point type
    Primary
    End point timeframe
    Baseline, EOT of Cycle 3 (up to 72 weeks)
    Notes
    [15] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No statistical and comparison analyses were performed for this endpoint.
    End point values
    Total Children (Aged: 1 to 15 Years) Infants (Corrected Gestational Age: 4 to < 12 Months)
    Number of subjects analysed
    6
    1
    Units: Z-score
        arithmetic mean (standard deviation)
    0.098 ( 0.3467 )
    3.554 ( 99999 )
    No statistical analyses for this end point

    Primary: Change From Baseline in Height For Age Z-Score at EOT of Cycle 4 During Teduglutide Treatment

    Close Top of page
    End point title
    Change From Baseline in Height For Age Z-Score at EOT of Cycle 4 During Teduglutide Treatment [16]
    End point description
    Height was measured using Age Z-Score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age >= 2 years old) and World Health Organization (age < 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Safety population. Here, "number of participants analysed" refer to the participants evaluable for this endpoint. Baseline refers to the baseline value of the core study (SHP633-302 [2020-005791-35]). Here, '99999' indicates that standard deviation could not be estimated for single subject for the specified arm.
    End point type
    Primary
    End point timeframe
    Baseline, EOT of Cycle 4 (up to 96 weeks)
    Notes
    [16] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No statistical and comparison analyses were performed for this endpoint.
    End point values
    Total Children (Aged: 1 to 15 Years) Infants (Corrected Gestational Age: 4 to < 12 Months)
    Number of subjects analysed
    5
    1
    Units: Z-score
        arithmetic mean (standard deviation)
    0.126 ( 0.2622 )
    3.542 ( 99999 )
    No statistical analyses for this end point

    Primary: Change From Baseline in Height For Age Z-Score at EOT of Cycle 5 During Teduglutide Treatment

    Close Top of page
    End point title
    Change From Baseline in Height For Age Z-Score at EOT of Cycle 5 During Teduglutide Treatment [17]
    End point description
    Height was measured using Age Z-Score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age >= 2 years old) and World Health Organization (age < 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Safety population. Here, "number of participants analysed" refer to the participants evaluable for this endpoint. Baseline refers to the baseline value of the core study (SHP633-302 [2020-005791-35]).
    End point type
    Primary
    End point timeframe
    Baseline, EOT of Cycle 5 (up to 120 weeks)
    Notes
    [17] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No statistical and comparison analyses were performed for this endpoint.
    End point values
    Total Children (Aged: 1 to 15 Years) Infants (Corrected Gestational Age: 4 to < 12 Months)
    Number of subjects analysed
    3
    0 [18]
    Units: Z-score
        arithmetic mean (standard deviation)
    0.342 ( 0.1012 )
    ( )
    Notes
    [18] - As no participant was analyzed for this arm, therefore data was not reported.
    No statistical analyses for this end point

    Primary: Change From Baseline in Height For Age Z-Score at EOT of Cycle 6 During Teduglutide Treatment

    Close Top of page
    End point title
    Change From Baseline in Height For Age Z-Score at EOT of Cycle 6 During Teduglutide Treatment [19]
    End point description
    Height was measured using Age Z-Score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age >= 2 years old) and World Health Organization (age < 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Safety population. Here, "number of participants analysed" refer to the participants evaluable for this endpoint. Baseline refers to the baseline value of the core study (SHP633-302 [2020-005791-35]).
    End point type
    Primary
    End point timeframe
    Baseline, EOT of Cycle 6 (up to 144 weeks)
    Notes
    [19] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No statistical and comparison analyses were performed for this endpoint.
    End point values
    Total Children (Aged: 1 to 15 Years) Infants (Corrected Gestational Age: 4 to < 12 Months)
    Number of subjects analysed
    2
    0 [20]
    Units: Z-Score
        arithmetic mean (standard deviation)
    0.276 ( 0.2593 )
    ( )
    Notes
    [20] - As no participant was analyzed for this arm, therefore data was not reported.
    No statistical analyses for this end point

    Primary: Change From Baseline in Height For Age Z-Score at EOT of Cycle 7 During Teduglutide Treatment

    Close Top of page
    End point title
    Change From Baseline in Height For Age Z-Score at EOT of Cycle 7 During Teduglutide Treatment [21]
    End point description
    Height was measured using Age Z-Score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age >= 2 years old) and World Health Organization (age < 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Safety population. Here, "number of participants analysed" refer to the participants evaluable for this endpoint. Baseline refers to the baseline value of the core study (SHP633-302 [2020-005791-35]). Here, '99999' indicates that standard deviation could not be estimated for single subject for the specified arm.
    End point type
    Primary
    End point timeframe
    Baseline, EOT of Cycle 7 (up to 168 weeks)
    Notes
    [21] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No statistical and comparison analyses were performed for this endpoint.
    End point values
    Total Children (Aged: 1 to 15 Years) Infants (Corrected Gestational Age: 4 to < 12 Months)
    Number of subjects analysed
    1
    0 [22]
    Units: Z-Score
        arithmetic mean (standard deviation)
    0.570 ( 99999 )
    ( )
    Notes
    [22] - As no participant was analyzed for this arm, therefore data was not reported.
    No statistical analyses for this end point

    Primary: Change From Baseline in Height For Age Z-Score at EOT of Cycle 8 During Teduglutide Treatment

    Close Top of page
    End point title
    Change From Baseline in Height For Age Z-Score at EOT of Cycle 8 During Teduglutide Treatment [23]
    End point description
    Height was measured using Age Z-Score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age >= 2 years old) and World Health Organization (age < 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Safety population. Here, "number of participants analysed" refer to the participants evaluable for this endpoint. Baseline refers to the baseline value of the core study (SHP633-302 [2020-005791-35]). Here, '99999' indicates that standard deviation could not be estimated for single subject for the specified arm.
    End point type
    Primary
    End point timeframe
    Baseline, EOT of Cycle 8 (up to 192 weeks)
    Notes
    [23] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No statistical and comparison analyses were performed for this endpoint.
    End point values
    Total Children (Aged: 1 to 15 Years) Infants (Corrected Gestational Age: 4 to < 12 Months)
    Number of subjects analysed
    1
    0 [24]
    Units: Z-Score
        arithmetic mean (standard deviation)
    0.851 ( 99999 )
    ( )
    Notes
    [24] - As no participant was analyzed for this arm, therefore data was not reported.
    No statistical analyses for this end point

    Primary: Change From Baseline in Height For Age Z-Score at EOT of Cycle 9 During Teduglutide Treatment

    Close Top of page
    End point title
    Change From Baseline in Height For Age Z-Score at EOT of Cycle 9 During Teduglutide Treatment [25]
    End point description
    Height was measured using Age Z-Score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age >= 2 years old) and World Health Organization (age < 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Safety population. Here, "number of participants analysed" refer to the participants evaluable for this endpoint. Baseline refers to the baseline value of the core study (SHP633-302 [2020-005791-35]). Here, '99999' indicates that standard deviation could not be estimated for single subject for the specified arm.
    End point type
    Primary
    End point timeframe
    Baseline, EOT of Cycle 9 (up to 196 weeks)
    Notes
    [25] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No statistical and comparison analyses were performed for this endpoint.
    End point values
    Total Children (Aged: 1 to 15 Years) Infants (Corrected Gestational Age: 4 to < 12 Months)
    Number of subjects analysed
    1
    0 [26]
    Units: Z-Score
        arithmetic mean (standard deviation)
    0.477 ( 99999 )
    ( )
    Notes
    [26] - As no participant was analyzed for this arm, therefore data was not reported.
    No statistical analyses for this end point

    Primary: Change From Baseline in Head Circumference for Age Z-score at EOT of Cycle 1 During Teduglutide Treatment

    Close Top of page
    End point title
    Change From Baseline in Head Circumference for Age Z-score at EOT of Cycle 1 During Teduglutide Treatment [27]
    End point description
    Head circumference was measured using Age Z-score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age >= 2 years old) and World Health Organization (age < 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Safety population. Here, "number of participants analysed" refer to the participants evaluable for this endpoint. Baseline refers to the baseline value of the core study (SHP633-302 [2020-005791-35]).
    End point type
    Primary
    End point timeframe
    Baseline, EOT of Cycle 1 (up to 24 weeks)
    Notes
    [27] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No statistical and comparison analyses were performed for this endpoint.
    End point values
    Total Children (Aged: 1 to 15 Years) Infants (Corrected Gestational Age: 4 to < 12 Months)
    Number of subjects analysed
    0 [28]
    2
    Units: Z-score
        arithmetic mean (standard deviation)
    ( )
    2.400 ( 0.6472 )
    Notes
    [28] - As no participant was analyzed for this arm, therefore data was not reported.
    No statistical analyses for this end point

    Primary: Change From Baseline in Head Circumference for Age Z-score at EOT of Cycle 2 During Teduglutide Treatment

    Close Top of page
    End point title
    Change From Baseline in Head Circumference for Age Z-score at EOT of Cycle 2 During Teduglutide Treatment [29]
    End point description
    Head circumference was measured using Age Z-score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age >= 2 years old) and World Health Organization (age < 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Safety population. Here, "number of participants analysed" refer to the participants evaluable for this endpoint. Baseline refers to the baseline value of the core study (SHP633-302 [2020-005791-35]). Here, '99999' indicates that standard deviation could not be estimated for single subject for the specified arm.
    End point type
    Primary
    End point timeframe
    Baseline, EOT of Cycle 2 (up to 48 weeks)
    Notes
    [29] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No statistical and comparison analyses were performed for this endpoint.
    End point values
    Total Children (Aged: 1 to 15 Years) Infants (Corrected Gestational Age: 4 to < 12 Months)
    Number of subjects analysed
    0 [30]
    1
    Units: Z-score
        arithmetic mean (standard deviation)
    ( )
    1.431 ( 99999 )
    Notes
    [30] - As no participant was analyzed for this arm, therefore data was not reported.
    No statistical analyses for this end point

    Primary: Change From Baseline in Head Circumference for Age Z-score at EOT of Cycle 3 During Teduglutide Treatment

    Close Top of page
    End point title
    Change From Baseline in Head Circumference for Age Z-score at EOT of Cycle 3 During Teduglutide Treatment [31]
    End point description
    Head circumference was measured using Age Z-score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age >= 2 years old) and World Health Organization (age < 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Safety population. Here, "number of participants analysed" refer to the participants evaluable for this endpoint. Baseline refers to the baseline value of the core study (SHP633-302 [2020-005791-35]). Here, '99999' indicates that standard deviation could not be estimated for single subject for the specified arm.
    End point type
    Primary
    End point timeframe
    Baseline, EOT of Cycle 3 (up to 72 weeks)
    Notes
    [31] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No statistical and comparison analyses were performed for this endpoint.
    End point values
    Total Children (Aged: 1 to 15 Years) Infants (Corrected Gestational Age: 4 to < 12 Months)
    Number of subjects analysed
    0 [32]
    1
    Units: Z-score
        arithmetic mean (standard deviation)
    ( )
    2.080 ( 99999 )
    Notes
    [32] - As no participant was analyzed for this arm, therefore data was not reported.
    No statistical analyses for this end point

    Primary: Change From Baseline in Head Circumference for Age Z-score at EOT of Cycle 4 During Teduglutide Treatment

    Close Top of page
    End point title
    Change From Baseline in Head Circumference for Age Z-score at EOT of Cycle 4 During Teduglutide Treatment [33]
    End point description
    Head circumference was measured using Age Z-score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age >= 2 years old) and World Health Organization (age < 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Safety population. Here, "number of participants analysed" refer to the participants evaluable for this endpoint. Baseline refers to the baseline value of the core study (SHP633-302 [2020-005791-35]). Here, '99999' indicates that standard deviation could not be estimated for single subject for the specified arm.
    End point type
    Primary
    End point timeframe
    Baseline, EOT of Cycle 4 (up to 76 weeks)
    Notes
    [33] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No statistical and comparison analyses were performed for this endpoint.
    End point values
    Total Children (Aged: 1 to 15 Years) Infants (Corrected Gestational Age: 4 to < 12 Months)
    Number of subjects analysed
    0 [34]
    1
    Units: Z-score
        arithmetic mean (standard deviation)
    ( )
    2.055 ( 99999 )
    Notes
    [34] - As no participant was analyzed for this arm, therefore data was not reported.
    No statistical analyses for this end point

    Primary: Change From Baseline in Body Mass Index (BMI) for Age Z-score at EOT of Cycle 1 During Teduglutide Treatment

    Close Top of page
    End point title
    Change From Baseline in Body Mass Index (BMI) for Age Z-score at EOT of Cycle 1 During Teduglutide Treatment [35]
    End point description
    BMI Z-score was calculated by using the height and weight Age Z-score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age >= 2 years old) and World Health Organization (age < 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Safety population. Here, "number of participants analysed" refer to the participants evaluable for this endpoint. Baseline refers to the baseline value of the core study (SHP633-302 [2020-005791-35]).
    End point type
    Primary
    End point timeframe
    Baseline, EOT of Cycle 1 (up to 24 weeks)
    Notes
    [35] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No statistical and comparison analyses were performed for this endpoint.
    End point values
    Total Children (Aged: 1 to 15 Years) Infants (Corrected Gestational Age: 4 to < 12 Months)
    Number of subjects analysed
    6
    0 [36]
    Units: Z-score
        arithmetic mean (standard deviation)
    0.090 ( 0.6642 )
    ( )
    Notes
    [36] - As no participant was analyzed for this arm, therefore data was not reported.
    No statistical analyses for this end point

    Primary: Change From Baseline in BMI for Age Z-score at EOT of Cycle 2 During Teduglutide Treatment

    Close Top of page
    End point title
    Change From Baseline in BMI for Age Z-score at EOT of Cycle 2 During Teduglutide Treatment [37]
    End point description
    BMI Z-score was calculated by using the height and weight Age Z-score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age >= 2 years old) and World Health Organization (age < 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Safety population. Here, "number of participants analysed" refer to the participants evaluable for this endpoint. Baseline refers to the baseline value of the core study (SHP633-302 [2020-005791-35]).
    End point type
    Primary
    End point timeframe
    Baseline, EOT of Cycle 2 (up to 48 weeks)
    Notes
    [37] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No statistical and comparison analyses were performed for this endpoint.
    End point values
    Total Children (Aged: 1 to 15 Years) Infants (Corrected Gestational Age: 4 to < 12 Months)
    Number of subjects analysed
    6
    0 [38]
    Units: Z-score
        arithmetic mean (standard deviation)
    0.489 ( 0.8474 )
    ( )
    Notes
    [38] - As no participant was analyzed for this arm, therefore data was not reported.
    No statistical analyses for this end point

    Primary: Change From Baseline in BMI for Age Z-score at EOT of Cycle 3 During Teduglutide Treatment

    Close Top of page
    End point title
    Change From Baseline in BMI for Age Z-score at EOT of Cycle 3 During Teduglutide Treatment [39]
    End point description
    BMI Z-score was calculated by using the height and weight Age Z-score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age >= 2 years old) and World Health Organization (age < 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Safety population. Here, "number of participants analysed" refer to the participants evaluable for this endpoint. Baseline refers to the baseline value of the core study (SHP633-302 [2020-005791-35]).
    End point type
    Primary
    End point timeframe
    Baseline, EOT of Cycle 3 (up to 72 weeks)
    Notes
    [39] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No statistical and comparison analyses were performed for this endpoint.
    End point values
    Total Children (Aged: 1 to 15 Years) Infants (Corrected Gestational Age: 4 to < 12 Months)
    Number of subjects analysed
    6
    0 [40]
    Units: Z-score
        arithmetic mean (standard deviation)
    0.409 ( 1.1688 )
    ( )
    Notes
    [40] - As no participant was analyzed for this arm, therefore data was not reported.
    No statistical analyses for this end point

    Primary: Change From Baseline in BMI for Age Z-score at EOT of Cycle 4 During Teduglutide Treatment

    Close Top of page
    End point title
    Change From Baseline in BMI for Age Z-score at EOT of Cycle 4 During Teduglutide Treatment [41]
    End point description
    BMI Z-score was calculated by using the height and weight Age Z-score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age >= 2 years old) and World Health Organization (age < 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Safety population. Here, "number of participants analysed" refer to the participants evaluable for this endpoint. Baseline refers to the baseline value of the core study (SHP633-302 [2020-005791-35]).
    End point type
    Primary
    End point timeframe
    Baseline, EOT of Cycle 4 (up to 96 weeks)
    Notes
    [41] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No statistical and comparison analyses were performed for this endpoint.
    End point values
    Total Children (Aged: 1 to 15 Years) Infants (Corrected Gestational Age: 4 to < 12 Months)
    Number of subjects analysed
    5
    0 [42]
    Units: Z-score
        arithmetic mean (standard deviation)
    0.118 ( 0.8827 )
    ( )
    Notes
    [42] - As no participant was analyzed for this arm, therefore data was not reported.
    No statistical analyses for this end point

    Primary: Change From Baseline in BMI for Age Z-score at EOT of Cycle 5 During Teduglutide Treatment

    Close Top of page
    End point title
    Change From Baseline in BMI for Age Z-score at EOT of Cycle 5 During Teduglutide Treatment [43]
    End point description
    BMI Z-score was calculated by using the height and weight Age Z-score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age >= 2 years old) and World Health Organization (age < 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Safety population. Here, "number of participants analysed" refer to the participants evaluable for this endpoint. Baseline refers to the baseline value of the core study (SHP633-302 [2020-005791-35]).
    End point type
    Primary
    End point timeframe
    Baseline, EOT of Cycle 5 (up to 120 weeks)
    Notes
    [43] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No statistical and comparison analyses were performed for this endpoint.
    End point values
    Total Children (Aged: 1 to 15 Years) Infants (Corrected Gestational Age: 4 to < 12 Months)
    Number of subjects analysed
    3
    0 [44]
    Units: Z-score
        arithmetic mean (standard deviation)
    0.070 ( 0.9770 )
    ( )
    Notes
    [44] - As no participant was analyzed for this arm, therefore data was not reported.
    No statistical analyses for this end point

    Primary: Change From Baseline in BMI for Age Z-score at EOT of Cycle 6 During Teduglutide Treatment

    Close Top of page
    End point title
    Change From Baseline in BMI for Age Z-score at EOT of Cycle 6 During Teduglutide Treatment [45]
    End point description
    BMI Z-score was calculated by using the height and weight Age Z-score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age >= 2 years old) and World Health Organization (age < 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Safety population. Here, "number of participants analysed" refer to the participants evaluable for this endpoint. Baseline refers to the baseline value of the core study (SHP633-302 [2020-005791-35]).
    End point type
    Primary
    End point timeframe
    Baseline, EOT of Cycle 6 (up to 144 weeks)
    Notes
    [45] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No statistical and comparison analyses were performed for this endpoint.
    End point values
    Total Children (Aged: 1 to 15 Years) Infants (Corrected Gestational Age: 4 to < 12 Months)
    Number of subjects analysed
    2
    0 [46]
    Units: Z-score
        arithmetic mean (standard deviation)
    0.925 ( 0.2556 )
    ( )
    Notes
    [46] - As no participant was analyzed for this arm, therefore data was not reported.
    No statistical analyses for this end point

    Primary: Change From Baseline in BMI for Age Z-score at EOT of Cycle 7 During Teduglutide Treatment

    Close Top of page
    End point title
    Change From Baseline in BMI for Age Z-score at EOT of Cycle 7 During Teduglutide Treatment [47]
    End point description
    BMI Z-score was calculated by using the height and weight Age Z-score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age >= 2 years old) and World Health Organization (age < 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Safety population. Here, "number of participants analysed" refer to the participants evaluable for this endpoint. Baseline refers to the baseline value of the core study (SHP633-302 [2020-005791-35]). Here, '99999' indicates that standard deviation could not be estimated for single subject for the specified arm.
    End point type
    Primary
    End point timeframe
    Baseline, EOT of Cycle 7 (up to 168 weeks)
    Notes
    [47] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No statistical and comparison analyses were performed for this endpoint.
    End point values
    Total Children (Aged: 1 to 15 Years) Infants (Corrected Gestational Age: 4 to < 12 Months)
    Number of subjects analysed
    1
    0 [48]
    Units: Z-score
        arithmetic mean (standard deviation)
    0.839 ( 99999 )
    ( )
    Notes
    [48] - As no participant was analyzed for this arm, therefore data was not reported.
    No statistical analyses for this end point

    Primary: Change From Baseline in BMI for Age Z-score at EOT of Cycle 8 During Teduglutide Treatment

    Close Top of page
    End point title
    Change From Baseline in BMI for Age Z-score at EOT of Cycle 8 During Teduglutide Treatment [49]
    End point description
    BMI Z-score was calculated by using the height and weight Age Z-score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age >= 2 years old) and World Health Organization (age < 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Safety population. Here, "number of participants analysed" refer to the participants evaluable for this endpoint. Baseline refers to the baseline value of the core study (SHP633-302 [2020-005791-35]). Here, '99999' indicates that standard deviation could not be estimated for single subject for the specified arm.
    End point type
    Primary
    End point timeframe
    Baseline, EOT of Cycle 8 (up to 192 weeks)
    Notes
    [49] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No statistical and comparison analyses were performed for this endpoint.
    End point values
    Total Children (Aged: 1 to 15 Years) Infants (Corrected Gestational Age: 4 to < 12 Months)
    Number of subjects analysed
    1
    0 [50]
    Units: Z-score
        arithmetic mean (standard deviation)
    0.015 ( 99999 )
    ( )
    Notes
    [50] - As no participant was analyzed for this arm, therefore data was not reported.
    No statistical analyses for this end point

    Primary: Change From Baseline in BMI for Age Z-score at EOT of Cycle 9 During Teduglutide Treatment

    Close Top of page
    End point title
    Change From Baseline in BMI for Age Z-score at EOT of Cycle 9 During Teduglutide Treatment [51]
    End point description
    BMI Z-score was calculated by using the height and weight Age Z-score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age >= 2 years old) and World Health Organization (age < 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Safety population. Here, "number of participants analysed" refer to the participants evaluable for this endpoint. Baseline refers to the baseline value of the core study (SHP633-302 [2020-005791-35]). Here, '99999' indicates that standard deviation could not be estimated for single subject for the specified arm.
    End point type
    Primary
    End point timeframe
    Baseline, EOT of Cycle 9 (up to 196 weeks)
    Notes
    [51] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No statistical and comparison analyses were performed for this endpoint.
    End point values
    Total Children (Aged: 1 to 15 Years) Infants (Corrected Gestational Age: 4 to < 12 Months)
    Number of subjects analysed
    1
    0 [52]
    Units: Z-score
        arithmetic mean (standard deviation)
    0.480 ( 99999 )
    ( )
    Notes
    [52] - As no participant was analyzed for this arm, therefore data was not reported.
    No statistical analyses for this end point

    Secondary: Number of Participants Who Achieved At Least 20 Percent (%) Reduction From Baseline in Participants Diary Parenteral Support (PS) Volume at EOT of Each Cycle During Teduglutide Treatment

    Close Top of page
    End point title
    Number of Participants Who Achieved At Least 20 Percent (%) Reduction From Baseline in Participants Diary Parenteral Support (PS) Volume at EOT of Each Cycle During Teduglutide Treatment
    End point description
    PS (parenteral nutrition or intravenous fluids) was considered for managing nutritional support in terms of volume during the treatment period. Percent reduction in weight-normalized diary PS values from baseline was calculated using the formula: % reduction in PS value at the visit = ([average daily value at the scheduled visit – average daily value at baseline of the core study (SHP633-302 [2020-005791-35]) / average daily value at baseline of the core study (SHP633-302 [2020-005791-35])) *100. Number of participants who achieved at least 20% reduction from baseline in participants diary PS volume at EOT of each cycle during teduglutide treatment were reported. Baseline refers to the baseline value of the core study (SHP633-302 [2020-005791-35]). Safety population. Here, "number of participants analysed" signifies participants who were evaluable for this endpoint and "n" signifies to participants evaluable at given timepoints.
    End point type
    Secondary
    End point timeframe
    Baseline, EOT of each cycle 1, 2, 3, 4, 5, 6, 7, 8 and 9 (Each Cycle 1 to 8 = 24 weeks, and Cycle 9 = 4 weeks)
    End point values
    Total Children (Aged: 1 to 15 Years) Infants (Corrected Gestational Age: 4 to < 12 Months)
    Number of subjects analysed
    6
    2
    Units: Participants
        At EOT of Cycle 1 (n= 6, 2)
    4
    1
        At EOT of Cycle 2 (n= 6, 1)
    4
    1
        At EOT of Cycle 3 (n= 6, 1)
    6
    1
        At EOT of Cycle 4 (n= 5, 1)
    5
    1
        At EOT of Cycle 5 (n= 3, 0)
    3
    0
        At EOT of Cycle 6 (n= 2, 0)
    2
    0
        At EOT of Cycle 7 (n= 1, 0)
    1
    0
        At EOT of Cycle 8 (n= 1, 0)
    1
    0
        At EOT of Cycle 9 (n= 1, 0)
    1
    0
    No statistical analyses for this end point

    Secondary: Number of Participants Who Achieved At Least 20 Percent (%) Reduction From Baseline in Investigator Prescribed PS Volume at EOT of Each Cycle During Teduglutide Treatment

    Close Top of page
    End point title
    Number of Participants Who Achieved At Least 20 Percent (%) Reduction From Baseline in Investigator Prescribed PS Volume at EOT of Each Cycle During Teduglutide Treatment
    End point description
    PS (parenteral nutrition or intravenous fluids) was considered for managing nutritional support in terms of volume during the treatment period. Percent reduction in weight-normalized prescribed PS values from baseline was calculated using the formula: % reduction in PS value at the visit =([average daily value at the scheduled visit – average daily value at baseline of the core study (SHP633-302 [2020-005791-35]) / average daily value at baseline of the core study (SHP633-302 [2020-005791-35])) *100. Number of participants who achieved at least 20% reduction from baseline in investigator prescribed PS volume at EOT of each cycle during teduglutide treatment were reported. Baseline refers to the baseline value of the core study (SHP633-302 [2020-005791-35]). Safety population. Here, "number of participants analysed" signifies participants who were evaluable for this endpoint and "n" signifies to participants evaluable at given timepoints.
    End point type
    Secondary
    End point timeframe
    Baseline, EOT of each cycle 1, 2, 3, 4, 5, 6, 7, 8 and 9 (Each Cycle 1 to 8 = 24 weeks, and Cycle 9 = 4 weeks)
    End point values
    Total Children (Aged: 1 to 15 Years) Infants (Corrected Gestational Age: 4 to < 12 Months)
    Number of subjects analysed
    6
    2
    Units: Participants
        At EOT of Cycle 1 (n= 6, 2)
    5
    1
        At EOT of Cycle 2 (n= 6, 1)
    5
    1
        At EOT of Cycle 3 (n= 6, 1)
    6
    1
        At EOT of Cycle 4 (n= 5, 1)
    5
    1
        At EOT of Cycle 5 (n= 3, 0)
    3
    0
        At EOT of Cycle 6 (n= 2, 0)
    2
    0
        At EOT of Cycle 7 (n= 1, 0)
    1
    0
        At EOT of Cycle 8 (n= 1, 0)
    1
    0
        At EOT of Cycle 9 (n= 1, 0)
    1
    0
    No statistical analyses for this end point

    Secondary: Change From Baseline in Participant Diary PS Volume at EOT of Each Cycle During Teduglutide Treatment

    Close Top of page
    End point title
    Change From Baseline in Participant Diary PS Volume at EOT of Each Cycle During Teduglutide Treatment
    End point description
    PS (parenteral nutrition or intravenous fluids) was considered for managing nutritional support in terms of volume during the treatment period. Change from baseline in participants diary PS volume at EOT of each cycle during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 [2020-005791-35]). Safety population. Here, "number of participants analysed" signifies participants who were evaluable for this endpoint and "n" signifies to participants evaluable at given timepoints. Here, '99999' indicates that standard deviation could not be estimated for single subject for the specified arm.
    End point type
    Secondary
    End point timeframe
    Baseline, EOT of each cycle 1, 2, 3, 4, 5, 6, 7, 8 and 9 (Each Cycle 1 to 8 = 24 weeks, and Cycle 9 = 4 weeks)
    End point values
    Total Children (Aged: 1 to 15 Years) Infants (Corrected Gestational Age: 4 to < 12 Months)
    Number of subjects analysed
    6
    2
    Units: mL/kg/day
    arithmetic mean (standard deviation)
        Change at EOT of Cycle 1 (n= 6, 2)
    -21.5 ( 11.83 )
    -31.9 ( 16.24 )
        Change at EOT of Cycle 2 (n= 6, 1)
    -25.5 ( 14.38 )
    -54.2 ( 99999 )
        Change at EOT of Cycle 3 (n= 6, 1)
    -32.1 ( 18.19 )
    -62.8 ( 99999 )
        Change at EOT of Cycle 4 (n= 5, 1)
    -37.2 ( 24.10 )
    -95.8 ( 99999 )
        Change at EOT of Cycle 5 (n= 3, 0)
    -54.8 ( 26.58 )
    9999 ( 9999 )
        Change at EOT of Cycle 6 (n= 2, 0)
    -63.8 ( 31.57 )
    9999 ( 9999 )
        Change at EOT of Cycle 7 (n= 1, 0)
    -93.8 ( 99999 )
    9999 ( 9999 )
        Change at EOT of Cycle 8 (n= 1, 0)
    -80.3 ( 99999 )
    9999 ( 9999 )
        Change at EOT of Cycle 9 (n= 1, 0)
    -79.1 ( 99999 )
    9999 ( 9999 )
    No statistical analyses for this end point

    Secondary: Percent Change From Baseline in Participant Diary PS Volume at EOT of Each Cycle During Teduglutide Treatment

    Close Top of page
    End point title
    Percent Change From Baseline in Participant Diary PS Volume at EOT of Each Cycle During Teduglutide Treatment
    End point description
    PS (parenteral nutrition or intravenous fluids) was considered for managing nutritional support in terms of volume during the treatment period. Percent change from baseline in participants diary PS volume at EOT of each cycle during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 [2020-005791-35]). Safety population. Here, "number of participants analysed" signifies participants who were evaluable for this endpoint and "n" signifies to participants evaluable at given timepoints. Here, '99999' indicates that standard deviation could not be estimated for single subject for the specified arm.
    End point type
    Secondary
    End point timeframe
    Baseline, EOT of each cycle 1, 2, 3, 4, 5, 6, 7, 8 and 9 (Each Cycle 1 to 8 = 24 weeks, and Cycle 9 = 4 weeks)
    End point values
    Total Children (Aged: 1 to 15 Years) Infants (Corrected Gestational Age: 4 to < 12 Months)
    Number of subjects analysed
    6
    2
    Units: Percent change
    arithmetic mean (standard deviation)
        Percent change at EOT of Cycle 1 (n=6, 2)
    -39.6 ( 34.86 )
    -32.5 ( 18.10 )
        Percent change at EOT of Cycle 2 (n=6, 1)
    -44.3 ( 33.11 )
    -56.6 ( 99999 )
        Percent change at EOT of Cycle 3 (n=6, 1)
    -52.8 ( 28.54 )
    -65.6 ( 99999 )
        Percent change at EOT of Cycle 4 (n=5, 1)
    -62.9 ( 26.18 )
    -100.0 ( 99999 )
        Percent change at EOT of Cycle 5 (n=3, 0)
    -73.9 ( 5.30 )
    9999 ( 9999 )
        Percent change at EOT of Cycle 6 (n=2, 0)
    -75.7 ( 0.54 )
    9999 ( 9999 )
        Percent change at EOT of Cycle 7 (n=1, 0)
    -82.9 ( 99999 )
    9999 ( 9999 )
        Percent change at EOT of Cycle 8 (n=1, 0)
    -70.9 ( 99999 )
    9999 ( 9999 )
        Percent change at EOT of Cycle 9 (n=1, 0)
    -69.8 ( 99999 )
    9999 ( 9999 )
    No statistical analyses for this end point

    Secondary: Change From Baseline in Investigator Prescribed PS Volume at EOT of Each Cycle During Teduglutide Treatment

    Close Top of page
    End point title
    Change From Baseline in Investigator Prescribed PS Volume at EOT of Each Cycle During Teduglutide Treatment
    End point description
    PS (parenteral nutrition or intravenous fluids) was considered for managing nutritional support in terms of volume during the treatment period. Change from baseline in investigator prescribed PS volume at EOT of each cycle during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 [2020-005791-35]). Safety population. Here, "number of participants analysed" signifies participants who were evaluable for this endpoint and "n" signifies to participants evaluable at given timepoints. Here, '99999' indicates that standard deviation could not be estimated for single subject for the specified arm.
    End point type
    Secondary
    End point timeframe
    Baseline, EOT of each cycle 1, 2, 3, 4, 5, 6, 7, 8 and 9 (Each Cycle 1 to 8 = 24 weeks, and Cycle 9 = 4 weeks)
    End point values
    Total Children (Aged: 1 to 15 Years) Infants (Corrected Gestational Age: 4 to < 12 Months)
    Number of subjects analysed
    6
    2
    Units: mL/kg/day
    arithmetic mean (standard deviation)
        Change at EOT of Cycle 1 (n= 6, 2)
    -20.9 ( 11.06 )
    -31.3 ( 26.77 )
        Change at EOT of Cycle 2 (n= 6, 1)
    -28.0 ( 13.51 )
    -60.6 ( 99999 )
        Change at EOT of Cycle 3 (n= 6, 1)
    -34.8 ( 21.13 )
    -67.5 ( 99999 )
        Change at EOT of Cycle 4 (n= 5, 1)
    -36.3 ( 23.52 )
    -98.7 ( 99999 )
        Change at EOT of Cycle 5 (n= 3, 0)
    -53.3 ( 26.24 )
    9999 ( 9999 )
        Change at EOT of Cycle 6 (n= 2, 0)
    -63.6 ( 32.10 )
    9999 ( 9999 )
        Change at EOT of Cycle 7 (n= 1, 0)
    -91.8 ( 99999 )
    9999 ( 9999 )
        Change at EOT of Cycle 8 (n= 1, 0)
    -77.3 ( 99999 )
    9999 ( 9999 )
        Change at EOT of Cycle 9 (n= 1, 0)
    -77.9 ( 99999 )
    9999 ( 9999 )
    No statistical analyses for this end point

    Secondary: Percent Change From Baseline in Investigator Prescribed PS Volume at EOT of Each Cycle During Teduglutide Treatment

    Close Top of page
    End point title
    Percent Change From Baseline in Investigator Prescribed PS Volume at EOT of Each Cycle During Teduglutide Treatment
    End point description
    PS (parenteral nutrition or intravenous fluids) was considered for managing nutritional support in terms of volume during the treatment period. Percent change from baseline in investigator prescribed PS volume at EOT of each cycle during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 [2020-005791-35]). Safety population. Here, "number of participants analysed" signifies participants who were evaluable for this endpoint and "n" signifies to participants evaluable at given timepoints. Here, '99999' indicates that standard deviation could not be estimated for single subject for the specified arm.
    End point type
    Secondary
    End point timeframe
    Baseline, EOT of each cycle 1, 2, 3, 4, 5, 6, 7, 8 and 9 (Each Cycle 1 to 8 = 24 weeks, and Cycle 9 = 4 weeks)
    End point values
    Total Children (Aged: 1 to 15 Years) Infants (Corrected Gestational Age: 4 to < 12 Months)
    Number of subjects analysed
    6
    2
    Units: Percent change
    arithmetic mean (standard deviation)
        Percent change at EOT of Cycle 1 (n= 6, 2)
    -38.8 ( 35.19 )
    -32.1 ( 26.51 )
        Percent change at EOT of Cycle 2 (n= 6, 1)
    -46.9 ( 30.42 )
    -61.4 ( 99999 )
        Percent change at EOT of Cycle 3 (n= 6, 1)
    -55.4 ( 27.78 )
    -68.3 ( 99999 )
        Percent change at EOT of Cycle 4 (n= 5, 1)
    -62.5 ( 26.45 )
    -100.0 ( 99999 )
        Percent change at EOT of Cycle 5 (n= 3, 0)
    -73.3 ( 5.51 )
    9999 ( 9999 )
        Percent change at EOT of Cycle 6 (n= 2, 0)
    -76.3 ( 2.41 )
    9999 ( 9999 )
        Percent change at EOT of Cycle 7 (n= 1, 0)
    -83.0 ( 99999 )
    9999 ( 9999 )
        Percent change at EOT of Cycle 8 (n= 1, 0)
    -69.9 ( 99999 )
    9999 ( 9999 )
        Percent change at EOT of Cycle 9 (n= 1, 0)
    -70.5 ( 99999 )
    9999 ( 9999 )
    No statistical analyses for this end point

    Secondary: Number of Participants Who Achieved Enteral Autonomy PS Volume at EOT of Each Cycle During Teduglutide Treatment

    Close Top of page
    End point title
    Number of Participants Who Achieved Enteral Autonomy PS Volume at EOT of Each Cycle During Teduglutide Treatment
    End point description
    Enteral autonomy (completely weaned off PS) was defined as the first visit where there is no use of PS for the 7 days prior to the visit and there is no prescribed PS at that visit, and the participants remains off PS for the remainder of the treatment period of that cycle. Number of participants who achieved enteral autonomy off PS volume at EOT of each cycle during teduglutide treatment were reported. Safety population. Here, "number of participants analysed" signifies participants who were evaluable for this endpoint and "n" signifies to participants evaluable at given timepoints. Baseline refers to the baseline value of the core study (SHP633-302 [2021-005404-36]). Here, '99999' indicates that standard deviation could not be estimated for single subject for the specified arm.
    End point type
    Secondary
    End point timeframe
    Baseline, EOT of each cycle 1, 2, 3, 4, 5, 6, 7, 8 and 9 (Each Cycle 1 to 8 = 24 weeks, and Cycle 9 = 4 weeks)
    End point values
    Total Children (Aged: 1 to 15 Years) Infants (Corrected Gestational Age: 4 to < 12 Months)
    Number of subjects analysed
    6
    2
    Units: Participants
        At EOT of Cycle 1 (n= 6, 2)
    1
    0
        At EOT of Cycle 2 (n= 6, 1)
    1
    0
        At EOT of Cycle 3 (n= 6, 1)
    1
    0
        At EOT of Cycle 4 (n= 5, 1)
    1
    1
        At EOT of Cycle 5 (n= 3, 0)
    0
    0
        At EOT of Cycle 6 (n= 2, 0)
    0
    0
        At EOT of Cycle 7 (n= 1, 0)
    0
    0
        At EOT of Cycle 8 (n= 1, 0)
    0
    0
        At EOT of Cycle 9 (n= 1, 0)
    0
    0
    No statistical analyses for this end point

    Secondary: Change From Baseline in Days Per Week of Diary PS Usage at EOT of Each Cycle During Teduglutide Treatment

    Close Top of page
    End point title
    Change From Baseline in Days Per Week of Diary PS Usage at EOT of Each Cycle During Teduglutide Treatment
    End point description
    Days per week of diary PS was calculated as: Days per week of actual PS = (number of days with non-zero values for PS volume within the 7 days prior to the visit / number of days for which any PS intake data was recorded within the 7 days prior to the visit) * 7. Change from baseline in days per week of diary PS usage at EOT of each cycle during teduglutide treatment was reported. Safety population. Here, "number of participants analysed" signifies participants who were evaluable for this endpoint and "n" signifies to participants evaluable at given timepoints. Baseline refers to the baseline value of the core study (SHP633-302 [2021-005404-36]).Here, '99999' indicates that standard deviation could not be estimated for single subject for the specified arm and "9999" indicates mean and SD could not estimated as no participant were analysed for specified arm
    End point type
    Secondary
    End point timeframe
    Baseline, EOT of each cycle 1, 2, 3, 4, 5, 6, 7, 8 and 9 (Each Cycle 1 to 8 = 24 weeks, and Cycle 9 = 4 weeks)
    End point values
    Total Children (Aged: 1 to 15 Years) Infants (Corrected Gestational Age: 4 to < 12 Months)
    Number of subjects analysed
    6
    2
    Units: Days/week
    arithmetic mean (standard deviation)
        Change at EOT of Cycle 1 (n= 6, 2)
    -1.2 ( 2.86 )
    0.0 ( 0.00 )
        Change at EOT of Cycle 2 (n= 6, 1)
    -1.2 ( 2.86 )
    0.0 ( 99999 )
        Change at EOT of Cycle 3 (n= 6, 1)
    -1.2 ( 2.86 )
    0.0 ( 99999 )
        Change at EOT of Cycle 4 (n= 5, 1)
    -1.4 ( 3.13 )
    -7.0 ( 99999 )
        Change at EOT of Cycle 5 (n= 3, 0)
    0.0 ( 0.00 )
    9999 ( 9999 )
        Change at EOT of Cycle 6 (n= 2, 0)
    0.0 ( 0.00 )
    9999 ( 9999 )
        Change at EOT of Cycle 7 (n= 1, 0)
    0.0 ( 99999 )
    9999 ( 9999 )
        Change at EOT of Cycle 8 (n= 1, 0)
    0.0 ( 99999 )
    9999 ( 9999 )
        Change at EOT of Cycle 9 (n= 1, 0)
    0.0 ( 99999 )
    9999 ( 9999 )
    No statistical analyses for this end point

    Secondary: Change From Baseline in Days Per Week of Prescribed PS Usage at EOT of Each Cycle During Teduglutide Treatment

    Close Top of page
    End point title
    Change From Baseline in Days Per Week of Prescribed PS Usage at EOT of Each Cycle During Teduglutide Treatment
    End point description
    Days per week of Prescribed PS was calculated as: Days per week of actual PS = (number of days with non-zero values for PS volume within the 7 days prior to the visit / number of days for which any PS intake data was recorded within the 7 days prior to the visit) * 7. Change from baseline in days Per week of prescribed PS usage at EOT of each cycle during teduglutide treatment was reported. Safety population. Here, "number of participants analysed" signifies participants who were evaluable for this endpoint and "n" signifies to participants evaluable at given timepoints. Baseline refers to the baseline value of the core study (SHP633-302 [2021-005404-36]). Here, '99999' indicates that standard deviation could not be estimated for single subject for the specified arm and "9999" indicates mean and SD could not be estimated as no participant were analysed for specified arm.
    End point type
    Secondary
    End point timeframe
    Baseline, EOT of each cycle 1, 2, 3, 4, 5, 6, 7, 8 and 9 (Each Cycle 1 to 8 = 24 weeks, and Cycle 9 = 4 weeks)
    End point values
    Total Children (Aged: 1 to 15 Years) Infants (Corrected Gestational Age: 4 to < 12 Months)
    Number of subjects analysed
    6
    2
    Units: Days/week
    arithmetic mean (standard deviation)
        Change at EOT of Cycle 1 (n= 6, 2)
    -1.2 ( 2.86 )
    0.0 ( 0.00 )
        Change at EOT of Cycle 2 (n= 6, 1)
    -1.2 ( 2.86 )
    0.0 ( 99999 )
        Change at EOT of Cycle 3 (n= 6, 1)
    -1.2 ( 2.86 )
    0.0 ( 99999 )
        Change at EOT of Cycle 4 (n= 5, 1)
    -1.4 ( 3.13 )
    -7.0 ( 99999 )
        Change at EOT of Cycle 5 (n= 3, 0)
    0.0 ( 0.00 )
    9999 ( 9999 )
        Change at EOT of Cycle 6 (n= 2, 0)
    0.0 ( 0.00 )
    9999 ( 9999 )
        Change at EOT of Cycle 7 (n= 1, 0)
    0.0 ( 99999 )
    9999 ( 9999 )
        Change at EOT of Cycle 8 (n= 1, 0)
    0.0 ( 99999 )
    9999 ( 9999 )
        Change at EOT of Cycle 9 (n= 1, 0)
    0.0 ( 99999 )
    9999 ( 9999 )
    No statistical analyses for this end point

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    From baseline up to follow-up (up to 50 months)
    Assessment type
    Non-systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    20.0
    Reporting groups
    Reporting group title
    Infants (Corrected Gestational Age: 4 to < 12 Months)
    Reporting group description
    Participants (Infants) from 4 through < 12 months of corrected gestational age who participated in the core study (SHP633-302 [2020-005791-35]) were enrolled into this extension study and received teduglutide 0.05 mg/kg SC injection for 24 weeks in each treatment cycle (Cycles 1 to 9 [Each cycle=28 weeks]) depending on the disease course.

    Reporting group title
    Total Children (Aged: 1 to 15 Years)
    Reporting group description
    Participants aged from 1 through 15 years who participated in the core study (SHP633-302 [2020-005791-35]) were enrolled into this extension study and received teduglutide 0.05 mg/kg SC injection for 24 weeks in each treatment cycle (Cycles 1 to 9 [Each cycle=28 weeks]) depending on the disease course.

    Serious adverse events
    Infants (Corrected Gestational Age: 4 to < 12 Months) Total Children (Aged: 1 to 15 Years)
    Total subjects affected by serious adverse events
         subjects affected / exposed
    2 / 2 (100.00%)
    7 / 7 (100.00%)
         number of deaths (all causes)
    0
    0
         number of deaths resulting from adverse events
    0
    0
    Surgical and medical procedures
    Central venous catheter removal
         subjects affected / exposed
    0 / 2 (0.00%)
    1 / 7 (14.29%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Nervous system disorders
    Seizure
         subjects affected / exposed
    1 / 2 (50.00%)
    0 / 7 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    General disorders and administration site conditions
    Pyrexia
         subjects affected / exposed
    0 / 2 (0.00%)
    1 / 7 (14.29%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Gastrointestinal disorders
    Colonic haematoma
         subjects affected / exposed
    0 / 2 (0.00%)
    1 / 7 (14.29%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Enteritis
         subjects affected / exposed
    0 / 2 (0.00%)
    1 / 7 (14.29%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Enterocolitis
         subjects affected / exposed
    0 / 2 (0.00%)
    1 / 7 (14.29%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Ileus
         subjects affected / exposed
    0 / 2 (0.00%)
    1 / 7 (14.29%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pancreatitis acute
         subjects affected / exposed
    1 / 2 (50.00%)
    0 / 7 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Vomiting
         subjects affected / exposed
    0 / 2 (0.00%)
    1 / 7 (14.29%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Infections and infestations
    Arthritis bacterial
         subjects affected / exposed
    0 / 2 (0.00%)
    1 / 7 (14.29%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Beta haemolytic streptococcal infection
         subjects affected / exposed
    0 / 2 (0.00%)
    1 / 7 (14.29%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Device related infection
         subjects affected / exposed
    1 / 2 (50.00%)
    4 / 7 (57.14%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 6
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Gastroenteritis adenovirus
         subjects affected / exposed
    1 / 2 (50.00%)
    0 / 7 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Medical device site infection
         subjects affected / exposed
    0 / 2 (0.00%)
    1 / 7 (14.29%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Otitis media
         subjects affected / exposed
    1 / 2 (50.00%)
    0 / 7 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Streptococcal infection
         subjects affected / exposed
    0 / 2 (0.00%)
    1 / 7 (14.29%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Upper respiratory tract infection
         subjects affected / exposed
    1 / 2 (50.00%)
    0 / 7 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Viral pharyngitis
         subjects affected / exposed
    0 / 2 (0.00%)
    1 / 7 (14.29%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Viral upper respiratory tract infection
         subjects affected / exposed
    1 / 2 (50.00%)
    0 / 7 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Product issues
    Device breakage
         subjects affected / exposed
    1 / 2 (50.00%)
    3 / 7 (42.86%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 8
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Device damage
         subjects affected / exposed
    0 / 2 (0.00%)
    2 / 7 (28.57%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Device occlusion
         subjects affected / exposed
    0 / 2 (0.00%)
    1 / 7 (14.29%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Metabolism and nutrition disorders
    Metabolic acidosis
         subjects affected / exposed
    0 / 2 (0.00%)
    1 / 7 (14.29%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    Infants (Corrected Gestational Age: 4 to < 12 Months) Total Children (Aged: 1 to 15 Years)
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    2 / 2 (100.00%)
    7 / 7 (100.00%)
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    Neoplasm
         subjects affected / exposed
    0 / 2 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    1
    General disorders and administration site conditions
    Injection site pain
         subjects affected / exposed
    0 / 2 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    1
    Injection site reaction
         subjects affected / exposed
    1 / 2 (50.00%)
    0 / 7 (0.00%)
         occurrences all number
    1
    0
    Pyrexia
         subjects affected / exposed
    0 / 2 (0.00%)
    3 / 7 (42.86%)
         occurrences all number
    0
    4
    Immune system disorders
    Food allergy
         subjects affected / exposed
    0 / 2 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    4
    Seasonal allergy
         subjects affected / exposed
    0 / 2 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    1
    Respiratory, thoracic and mediastinal disorders
    Asthma
         subjects affected / exposed
    0 / 2 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    1
    Cough
         subjects affected / exposed
    0 / 2 (0.00%)
    2 / 7 (28.57%)
         occurrences all number
    0
    2
    Epistaxis
         subjects affected / exposed
    0 / 2 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    1
    Rhinitis allergic
         subjects affected / exposed
    1 / 2 (50.00%)
    0 / 7 (0.00%)
         occurrences all number
    1
    0
    Rhinorrhoea
         subjects affected / exposed
    0 / 2 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    1
    Upper respiratory tract inflammation
         subjects affected / exposed
    0 / 2 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    1
    Psychiatric disorders
    Head banging
         subjects affected / exposed
    0 / 2 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    1
    Product issues
    Device damage
         subjects affected / exposed
    0 / 2 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    1
    Investigations
    Alanine aminotransferase increased
    alternative assessment type: Systematic
         subjects affected / exposed
    1 / 2 (50.00%)
    0 / 7 (0.00%)
         occurrences all number
    2
    0
    Amylase increased
    alternative assessment type: Systematic
         subjects affected / exposed
    0 / 2 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    1
    Aspartate aminotransferase increased
         subjects affected / exposed
    1 / 2 (50.00%)
    0 / 7 (0.00%)
         occurrences all number
    1
    0
    Blood alkaline phosphatase increased
         subjects affected / exposed
    1 / 2 (50.00%)
    0 / 7 (0.00%)
         occurrences all number
    1
    0
    Eosinophil count increased
         subjects affected / exposed
    1 / 2 (50.00%)
    0 / 7 (0.00%)
         occurrences all number
    1
    0
    Lipase increased
         subjects affected / exposed
    0 / 2 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    1
    Transaminases increased
         subjects affected / exposed
    0 / 2 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    1
    Injury, poisoning and procedural complications
    Auricular haematoma
         subjects affected / exposed
    1 / 2 (50.00%)
    0 / 7 (0.00%)
         occurrences all number
    1
    0
    Epiphyseal injury
         subjects affected / exposed
    0 / 2 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    1
    Contusion
         subjects affected / exposed
    1 / 2 (50.00%)
    0 / 7 (0.00%)
         occurrences all number
    1
    0
    Fracture
         subjects affected / exposed
    0 / 2 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    1
    Fall
         subjects affected / exposed
    0 / 2 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    1
    Gastrostomy tube site complication
         subjects affected / exposed
    0 / 2 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    1
    Heat stroke
         subjects affected / exposed
    0 / 2 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    1
    Injury corneal
         subjects affected / exposed
    0 / 2 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    1
    Ligament injury
         subjects affected / exposed
    0 / 2 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    1
    Procedural pain
         subjects affected / exposed
    0 / 2 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    1
    Wound complication
         subjects affected / exposed
    0 / 2 (0.00%)
    2 / 7 (28.57%)
         occurrences all number
    0
    2
    Blood and lymphatic system disorders
    Anaemia
         subjects affected / exposed
    0 / 2 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    1
    Eye disorders
    Conjunctivitis allergic
         subjects affected / exposed
    0 / 2 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    2
    Eye discharge
         subjects affected / exposed
    0 / 2 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    1
    Strabismus
         subjects affected / exposed
    0 / 2 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    1
    Gastrointestinal disorders
    Abdominal distension
         subjects affected / exposed
    0 / 2 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    2
    Abdominal pain
         subjects affected / exposed
    0 / 2 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    1
    Cheilitis
         subjects affected / exposed
    0 / 2 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    2
    Constipation
         subjects affected / exposed
    0 / 2 (0.00%)
    2 / 7 (28.57%)
         occurrences all number
    0
    2
    Dental caries
         subjects affected / exposed
    0 / 2 (0.00%)
    2 / 7 (28.57%)
         occurrences all number
    0
    2
    Enteritis
         subjects affected / exposed
    0 / 2 (0.00%)
    2 / 7 (28.57%)
         occurrences all number
    0
    5
    Enterocolitis
         subjects affected / exposed
    0 / 2 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    1
    Gastric disorder
         subjects affected / exposed
    0 / 2 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    1
    Lip dry
         subjects affected / exposed
    0 / 2 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    1
    Nausea
         subjects affected / exposed
    0 / 2 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    1
    Rectal prolapse
         subjects affected / exposed
    0 / 2 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    1
    Stomatitis
         subjects affected / exposed
    0 / 2 (0.00%)
    2 / 7 (28.57%)
         occurrences all number
    0
    2
    Hepatobiliary disorders
    Drug-induced liver injury
         subjects affected / exposed
    0 / 2 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    1
    Skin and subcutaneous tissue disorders
    Acne
         subjects affected / exposed
    0 / 2 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    1
    Dermatitis allergic
         subjects affected / exposed
    0 / 2 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    1
    Dermatitis
         subjects affected / exposed
    1 / 2 (50.00%)
    0 / 7 (0.00%)
         occurrences all number
    1
    0
    Dermatitis diaper
         subjects affected / exposed
    1 / 2 (50.00%)
    0 / 7 (0.00%)
         occurrences all number
    1
    0
    Drug eruption
         subjects affected / exposed
    0 / 2 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    1
    Dry skin
         subjects affected / exposed
    0 / 2 (0.00%)
    2 / 7 (28.57%)
         occurrences all number
    0
    2
    Eczema
         subjects affected / exposed
    0 / 2 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    2
    Haemorrhage subcutaneous
         subjects affected / exposed
    0 / 2 (0.00%)
    2 / 7 (28.57%)
         occurrences all number
    0
    2
    Miliaria
         subjects affected / exposed
    0 / 2 (0.00%)
    2 / 7 (28.57%)
         occurrences all number
    0
    2
    Rash
         subjects affected / exposed
    0 / 2 (0.00%)
    3 / 7 (42.86%)
         occurrences all number
    0
    4
    Skin erosion
         subjects affected / exposed
    0 / 2 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    1
    Skin induration
         subjects affected / exposed
    0 / 2 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    1
    Urticaria
         subjects affected / exposed
    0 / 2 (0.00%)
    2 / 7 (28.57%)
         occurrences all number
    0
    3
    Musculoskeletal and connective tissue disorders
    Joint swelling
         subjects affected / exposed
    0 / 2 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    1
    Myalgia
         subjects affected / exposed
    0 / 2 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    1
    Infections and infestations
    Adenoviral conjunctivitis
         subjects affected / exposed
    0 / 2 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    1
    Conjunctivitis
         subjects affected / exposed
    1 / 2 (50.00%)
    1 / 7 (14.29%)
         occurrences all number
    3
    1
    Epididymitis
         subjects affected / exposed
    0 / 2 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    1
    Hand-foot-and-mouth disease
         subjects affected / exposed
    0 / 2 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    1
    Gastroenteritis
         subjects affected / exposed
    0 / 2 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    1
    Influenza
         subjects affected / exposed
    0 / 2 (0.00%)
    2 / 7 (28.57%)
         occurrences all number
    0
    2
    Infected bite
         subjects affected / exposed
    0 / 2 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    1
    Medical device site infection
         subjects affected / exposed
    1 / 2 (50.00%)
    1 / 7 (14.29%)
         occurrences all number
    1
    1
    Oral candidiasis
         subjects affected / exposed
    1 / 2 (50.00%)
    0 / 7 (0.00%)
         occurrences all number
    1
    0
    Periodontitis
         subjects affected / exposed
    0 / 2 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    2
    Upper respiratory tract infection
         subjects affected / exposed
    1 / 2 (50.00%)
    0 / 7 (0.00%)
         occurrences all number
    2
    0
    Viral infection
         subjects affected / exposed
    1 / 2 (50.00%)
    0 / 7 (0.00%)
         occurrences all number
    1
    0
    Viral upper respiratory tract infection
         subjects affected / exposed
    1 / 2 (50.00%)
    4 / 7 (57.14%)
         occurrences all number
    5
    25
    Metabolism and nutrition disorders
    Dehydration
         subjects affected / exposed
    1 / 2 (50.00%)
    2 / 7 (28.57%)
         occurrences all number
    1
    6
    Hypomagnesaemia
         subjects affected / exposed
    0 / 2 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    1
    Hypozincaemia
         subjects affected / exposed
    0 / 2 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    1
    Metabolic acidosis
         subjects affected / exposed
    0 / 2 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    5

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    26 May 2017
    Amendment 1: - Clarification that medical history and SBS history collected at study entry were updates to data collected at the start of the core study. - Clarification that during the no-teduglutide treatment period, visits would take place approximately every 12 weeks. - Clarification that PS prescription was collected at the screening visit. - Sigmoidoscopy was added as the alternate to colonoscopy throughout the protocol. - Clarification that unscheduled laboratory tests were performed at the investigational site laboratory, as needed. - Clarification on visit schedule when a participant prematurely discontinues IP during a teduglutide treatment cycle. - Clarification on handling of an investigational drug, which is for single use only and should be used within 3 hours following reconstitution. - Removal of urine sodium from the list of urinalysis parameters to be tested.
    24 Jan 2018
    Amendment 2: - Revised investigational product (IP) administration language to provide oversight on IP administration. - Added direct bilirubin to the list of laboratory tests. - Clarifications that the drug administration diary can be completed by site staff, added “guardian” to replace “legally authorized representative”, and updated the emergency contact information and the product quality complaint section.
    20 Jul 2018
    Amendment 3: - Update of the number of participants from 5 to 7. - Addition of the study population of 2 cohorts based on age of participants at the time of entry into the core study: the infant cohort 4 to less than 12 months of corrected gestational age and children 1 to 15 years of age. - To minimize risk to participants, a new escape criterion was added allowing those who had escaped during the follow-up period of a previous teduglutide treatment cycle to omit the follow-up period during subsequent teduglutide treatment cycles. - Modified teduglutide treatment exclusion criterion 1 on participants body weight to accommodate younger children (exclude participants if weight less than 5 kg). - Clarified the requirement from the study physician to observe the parent/guardian administering the IP at least twice before permitting the parent/guardian to administer teduglutide to a single observation. - Clarified blood pressure collection to same extremity rather than same arm (arm is not used in small children). - Clarified that IP compliance is calculated from diaries. - Deleted the 4 hour observation period at initial dosing since participants were already exposed to teduglutide in the core study. - Omitted saved serum samples for participants less than 10 kg. - Updates for number of enrolled participants, corporate name change, medical monitor change, deletion of duplicate text, and other minor editorial corrections
    06 Nov 2020
    Amendment 4: - Sponsor name changed to include both Shire Human Genetic Therapies, Inc. (USA) and Takeda Pharmaceutical Company Limited. - Transferred back the role of in-country clinical caretaker from IQVIA Services Japan K.K to the sponsor. The sponsor is now responsible for notifying the relevant regulatory authorities of related, unexpected serious adverse events (SAEs). - Updated the end of the planned study period to December 2021. - Expanded the timing to perform a colonoscopy/sigmoidoscopy at the end of a teduglutide treatment cycle (CxW24). Participants who received 2 treatment cycles (48 weeks of teduglutide exposure) will undergo a colonoscopy/sigmoidoscopy before the next cycle of teduglutide treatment. Colonoscopy/sigmoidoscopy performed after the Visit CxW24 (±4 days) window and before the next cycle of teduglutide treatment will not be considered a protocol deviation. All other visit procedures must adhere to the (±4 days) visit window. - Added a new section entitled “Changes to Study Procedures Due to a Pandemic”. The purpose of these changes is to maintain the participant safety, confidentiality, and study integrity in the context of healthcare delivery challenges presented by the COVID-19 pandemic. - Clarified the definition of an overdose as the administration of the investigational product at a dose or frequency greater than 0.05 mg/kg subcutaneous once daily. An overdose occurs if any of the following criteria are met: * More than 0.05 mg/kg is given at any one time * Consecutive doses are spaced less than 12 hours apart * Any more than 0.05 mg/kg in one day - Changed the data monitoring committee meeting frequency. The DMC members will review the data approximately every 6 months (previously 3 months) during the study treatment periods (date of the first participants first dose to date of the last participants last dose). - Updated contact information and responsible personnel.

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 06 18:11:16 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA